Pharmaceutical companies Merck and Moderna have announced positive results from a large late-stage trial involving a personalized mRNA cancer vaccine designed to prevent melanoma from returning or spreading. The trial evaluated patients with localized tumors that were surgically removed but carried a high risk of recurrence.
Unlike traditional chemotherapy, which impacts both healthy and cancerous cells, or standard immunotherapy, personalized cancer vaccines train the immune system to specifically target mutations found only on an individual patient's tumor. The treatment, known as intismeran autogene, combines Merck's immunotherapy drug Keytruda with a customized mRNA vaccine.
The ongoing trial involved more than 1,000 melanoma patients. According to the companies, the addition of the vaccine showed no new serious side effects compared to Keytruda alone, with reported reactions similar to those experienced from flu or COVID-19 shots. Moderna expects that thousands of melanoma patients could benefit within the first few years of approval.
Medical experts have responded positively to the findings. Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute, noted that the positive study brings hope and anticipated investment that these approaches may change broader cancer treatment methodologies. Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology, described the result as a monumental leap forward for validating mRNA technology in oncology.
Building on these developments, personalized cancer vaccines are currently in various stages of clinical development across multiple tumor types. Merck and Moderna have several large trials underway in surgically removed non-small cell lung cancers, alongside mid-stage trials in bladder and kidney cancers, and early-stage trials in pancreatic and stomach cancers.
Other pharmaceutical players are also exploring similar methodologies. Roche and BioNTech are testing a comparable treatment called autogene cevumeran in mid-stage studies involving colon and pancreatic cancer patients who have undergone surgery. Results from the colon cancer trial are expected in 2027, followed by pancreatic trial results in 2031.
While the current trial remains ongoing and full results are yet to be published, the companies continue to track volunteers to assess whether the drug extends overall survival. Previous mid-stage trial data indicated that the vaccine reduced the risk of cancer return and spread compared to Keytruda alone, prompting further research into tumors that produce high rates of mutations.
"The clinical progress demonstrated by Moderna and Merck highlights the commercial and therapeutic viability of applying mRNA technology beyond infectious diseases. For the broader healthcare and biotech ecosystem, this milestone underscores how targeted innovation and strategic industry collaborations can create entirely new market segments. As late-stage trials expand into other oncology areas, we can expect increased capital allocation and investor interest in precision therapeutics and personalized medicine platforms." — Dr. Shishir Gupta, Founder & CEO, StartupLanes
